<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265836</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CTH-DUM-2010/1</org_study_id>
    <nct_id>NCT01265836</nct_id>
  </id_info>
  <brief_title>Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes</brief_title>
  <acronym>DEMAND</acronym>
  <official_title>Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the proportion of patients on lipid-lowering&#xD;
      pharmacological treatment (statin or combination) reaching the LDL-C goals according to the&#xD;
      updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)&#xD;
      guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MC MD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1064</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Provision of subject informed consent&#xD;
&#xD;
          2. Female or male aged = 18 years&#xD;
&#xD;
          3. Patients eligible for treatment of dyslipidemia with statins, according to the current&#xD;
             guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention.&#xD;
&#xD;
          4. Receiving lipid-lowering drug treatment for at least 15 days.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of subject informed consent, Female or male aged = 18 years&#xD;
&#xD;
          -  Patients eligible for treatment of dyslipidemia with statins, according to the current&#xD;
             guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving&#xD;
             lipid-lowering drug treatment for at least 15 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in the planning and conduct of the study (applies to either AstraZeneca&#xD;
             staff or staff at the study site).&#xD;
&#xD;
          -  Previous enrolment or randomisation of treatment in the present study&#xD;
&#xD;
          -  Participation in a clinical study during the last 90 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Apichard Sukonthasarn, Prof.M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maharaj Nakorn Chiangmai Hospital Cardiovascular division, Department of Internal Medicine, Faculty of Medicine, Chiangmai University</affiliation>
  </overall_official>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marketing Company Medical Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Dyslipidemia Treatment and Cardiovascular Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

